News & Updates
Showing Oncology articles
Showing
Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?
A landmark analysis of data from a Hong Kong prostate cancer database found that use of proton-pump inhibitors (PPIs) was associated with inferior oncological outcomes in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who received upfront docetaxel.
Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?
23 Sep 2025
Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?
Research findings from Yonsei Cancer Center in South Korea, presented at European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025, suggest a correlation between butyrate-producing Faecalibacterium enrichment and clinical response to pembrolizumab with or without chemotherapy in treatment-naïve patients with metastatic non-small-cell lung cancer (mNSCLC).
Can gut microbiome composition predict response to pembrolizumab +/- chemo in treatment-naïve mNSCLC?
23 Sep 2025
PORTEC-3: Adjuvant chemoradiotherapy improves 10-year OS in high-risk endometrial cancer
Adjuvant chemoradiotherapy (CRT) improves both 10-year overall survival (OS) and recurrence-free survival (RFS) in women with high-risk endometrial cancer vs pelvic radiotherapy alone, with the most clinically relevant benefit observed in p53 abnormal cancers, according to the 10-year analysis of the phase III PORTEC-3 trial.
